Still’s Disease Treatment has improved with the inclusion of both surgical and non-surgical procedures and newly approved treatment options
Still's disease is a rare respiratory
disorder that causes shortness of breath and coughing with some difficulty
breathing. A person with this condition will generally cough up phlegm which
he/she clears by exhaling through the mouth. Still's disease is an illness
caused by the interplay of various viruses, bacteria, and fungi, as well as
environmental toxins. The most common cause of this condition is tobacco
smoking, although stress, viral infections, and exposure to certain chemicals
also can lead to this disease. Although Still’s disease is rare, its estimated
crude prevalence among people aged 16 years and above is 0.73 to 1.47 per
100,000 population for males and females.
Still’ diseases can be categorized
into two stages, namely Stokes' Delivery. Stokes' disease is a severe
manifestation of Stills' disease. Stokes' disease is usually fatal but in some
cases, it can lead to pleural effusions and pneumonia. The treatment for
Stokes' disease usually involves aggressive therapy including steroids and antibiotics.
Therapy can be given to prevent the recurrence of symptoms such as cough.
Stills can be diagnosed by physical
examination of the lungs, chest x-rays, CT scans, and MRI tests. Still’s disease treatment usually involves anticoagulants, which reduce the
inflammation of the lining of the respiratory tract. Treatment can be surgical
or non-surgical. Non-surgical Still’s disease treatment can include fluid
therapy. Fluid therapy consists of low doses of intravenous fluids and
medications that increase the fluid capacity of the lungs. These fluids include
both arterial and venous solutions. There are no rules on how much of the fluid
to take. Most patients are treated within two weeks and required to drink
fluids for approximately six to eight weeks. Recently, the U.S. Food and Drug
Administration (FDA) approved the first treatment for adult-onset of the
Still’s disease while Japan’s Chugai received the approval for its Still’s
disease treatment Actemra.
Comments
Post a Comment